Latest News - Valeant NJ

Tuesday, November 14, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Valeant NJ

Ortho Dermatologics Announces Aspire Higher Scholarship Honorees

Ortho Dermatologics announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or four-y…

Read the full story

Thursday, November 02, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Product Launches and Updates, Valeant NJ

FDA Accepts Ortho Dermatologic’s NDA for Novel Plaque Psoriasis Treatment, IDP-118

The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatme…

Read the full story

Friday, October 13, 2017 | Personnel/Company News, PracticalDermatology.com, Solta, Valeant NJ

James P. Hartman Named New Vice President and General Manager at Solta Medical

James P. Hartman is the new Vice President and general manager at Solta Medical, a division of Valeant Pharmaceuticals North America LLC. Mr. Hartman joined Solta Medical from Merz Aesthetics (a di…

Read the full story

Wednesday, October 04, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Product Launches and Updates, Solta, Valeant NJ

Meet Thermage’s New FLX System

The US Food and Drug Administration granted 510(K) clearance to Solta Medical’s new Thermage FLXTM System for smoothing skin on the face, eyes, and body. The Thermage FLX features a…

Read the full story

Thursday, July 27, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Atopic Derm, Atopic Dermatitis , Eczema, Psoriasis, Valeant NJ

Valeant’s Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AAD

It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch …

Read the full story

Thursday, July 27, 2017 | Personnel/Company News, PracticalDermatology.com, Product Launches and Updates, Valeant NJ

Valeant Launches Siliq Injection for Psoriasis

 Valeant Pharmaceuticals International, Inc. launched Siliq (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York fro…

Read the full story

Tuesday, July 18, 2017 | Acquisitions and Mergers, PracticalDermatology.com, Obagi, Valeant NJ

Valeant to Sell Obagi Medical Products Business for $190 M

Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acqui…

Read the full story

Wednesday, May 17, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Valeant NJ

Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launch

Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman.  The team includes Michael McMyne, vice president of sales; Stac…

Read the full story

Monday, May 08, 2017 | Personnel/Company News, Valeant NJ

Valeant Appoints New Dermatology and Corporate Communications Leadership Members

Valeant Pharmaceuticals International, Inc. added new members to the dermatology leadership team -- Michael McMyne is the new Vice President of Sales and Stacey Williams is the new Vice President of M…

Read the full story

Friday, April 21, 2017 | PracticalDermatology.com, Product Launches and Updates, Valeant NJ

Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasis

Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per mon…

Read the full story

Tuesday, March 14, 2017 | Business of Medicine, Earnings and Financials, Valeant NJ

Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.

Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker:…

Read the full story

Thursday, February 23, 2017 | Personnel/Company News, Product Launches and Updates, Obagi, Valeant NJ

Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Line

Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s…

Read the full story

Thursday, February 16, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Valeant NJ

FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasis

The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor …

Read the full story

Wednesday, February 01, 2017 | Personnel/Company News, Valeant NJ

Valeant Dermatology to Award $10,000 Scholarships for Undergraduate and Graduate Degrees

Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, will award nine individual scholarships of up to $10,000 through its annual ASPIRE HIGHER Scholarship Program. The scholar…

Read the full story

Tuesday, January 10, 2017 | Personnel/Company News, PracticalDermatology.com, Product Launches and Updates, Valeant NJ

L'Oréal Buys CeraVe, AcneFree and AMBI from Valeant

Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in th…

Read the full story
Load More